Allogene Therapeutics, Inc. (ALLO) financial statements (2022 and earlier)

Company profile

Business Address 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:8101,000589721
Cash and cash equivalents17318317592
Short-term investments284645355367
Other undisclosed cash, cash equivalents, and short-term investments35217258262
Prepaid expense  53
Other undisclosed current assets(338)(155)(50)(257)
Total current assets:471845545468
Noncurrent Assets
Operating lease, right-of-use asset5841 
Property, plant and equipment123119569
Long-term investments and receivables37020863262
Long-term investments37020863262
Intangible assets, net (including goodwill)  01
Intangible assets, net (excluding goodwill)  01
Restricted cash and investments10941
Other noncurrent assets6550
Other undisclosed noncurrent assets  4433
Total noncurrent assets:567383173306
TOTAL ASSETS:1,0391,228718774
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1010912
Accounts payable1010912
Deferred revenue039 
Deferred compensation liability3335
Other liabilities5531
Other undisclosed current liabilities30371812
Total current liabilities:48943329
Noncurrent Liabilities
Long-term debt and lease obligation7051  
Operating lease, liability7051 
Liabilities, other than long-term debt43414
Deferred compensation liability, classified   7
Other liabilities4347
Other undisclosed noncurrent liabilities  5128
Total noncurrent liabilities:74545641
Total liabilities:1221488971
Stockholders' equity
Stockholders' equity attributable to parent9161,080629703
Common stock0000
Additional paid in capital1,8221,7261,024914
Accumulated other comprehensive income (loss)(3)010
Accumulated deficit(903)(646)(396)(212)
Total stockholders' equity:9161,080629703
TOTAL LIABILITIES AND EQUITY:1,0391,228718774

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues38   
Gross profit:38   
Operating expenses(294)(258)(202)(193)
Operating loss:(256)(258)(202)(193)
Nonoperating income (expense)(1)817(19)
Other nonoperating income29176
Interest and debt expense   (3)
Loss from continuing operations before equity method investments, income taxes:(257)(250)(185)(215)
Other undisclosed income from continuing operations before income taxes   3
Loss from continuing operations before income taxes:(257)(250)(185)(212)
Income tax benefit  00
Net loss available to common stockholders, diluted:(257)(250)(185)(212)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(257)(250)(185)(212)
Other comprehensive loss  (0)(0)
Comprehensive loss:(257)(250)(185)(212)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)(1)10
Comprehensive loss, net of tax, attributable to parent:(260)(251)(184)(211)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: